April 2021 Vol 7 No 2
In her introduction to the April 2021 issue, Lillie Shockney discusses several themes featured in this issue, including the link between climate change and skin cancer and the need to tackle infertility in young adults with cancer, as addressed by an advocacy group.
Patient StoriesBreast CancerCOVID-19 & Cancer
By Kiana Wooten
In May 2019, Kiana Wooten went for a routine check-up. Read about how that routine visit turned into a breast cancer diagnosis for the 34-year-old Kiana, who had to be hospitalized during COVID-19.
Art TherapyCOVID-19 & Cancer
Zack Luchetti, who has been teaching art remotely in the past year, initially thought he had COVID-19, then appendicitis, only to be told he had colon cancer. His 2 paintings represent a self-portrait of encouragement and the tie between cancer and coronavirus.
By Bethany Sell
Bethany Sell takes us through her thought process after learning she would have to lose her breasts to cancer, as she grapples with wishing to look “normal” but learning to embrace her new look.
Skin CancerPatient Stories
Mark Ryan, RN, is not worried about the impact of climate change on the weather, but on skin cancer, which he knows first-hand. A decrease in stratospheric ozone requires stringent environmental regulations to prevent cancer, he says.
Fertility PreservationFrom Your NavigatorPediatric Cancer
Read about the Ulman Foundation, a nonprofit organization that provides support to young adults with cancer, including fertility preservation services.
FDA Approvals, News & UpdatesLymphoma
“Today’s approval represents another milestone in the rapidly progressing field of gene therapy,” said Peter Marks, MD, PhD, Director of the FDA’s Center for Biologics Evaluation and Research.
FDA Approvals, News & UpdatesFollicular LymphomaLymphoma
Ukoniq is the first dual inhibitor of PI3K-delta and CK1-epsilon to be approved by the FDA, and is the first targeted, once-daily oral therapy option for marginal-zone or follicular lymphoma.
FDA Approvals, News & UpdatesFollicular Lymphoma
Yescarta is the first CAR T-cell therapy approved by the FDA for patients with follicular lymphoma. It uses the patient’s own genetically modified T-cells to fight the cancer.
Page 1 of 3
Results 1 - 10 of 23
Results 1 - 10 of 23